Press release content from Business Wire. The AP news staff was not involved in its creation.
New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials
January 12, 2021 GMT
MINNEAPOLIS (BUSINESS WIRE) Jan 12, 2021
OX2 Therapeutics, Inc., a privately held Minneapolis company, announces today that they treated their first patient in a phase one human trial of a new treatment developed to combat recurrent high-grade brain tumors.
“This is a first-of-its kind immunotherapy that works to treat one of the most aggressive and deadly cancers today,” said Christopher Moertel, MD, OX2 Therapeutics, Inc. “Central nervous system cancers are the number one cause of cancer related mortality in children, and a major cause of morbidity and mortality in adults.”